Ken Keller
Director & Head of Oncology Business
Replay available
Daiichi Sankyo Co Ltd Ord (DSKYF) Q2 2025 Earnings Call
Daiichi Sankyo Co Ltd Ord (OTC: DSKYF) Q2 2025 earnings conference call, held 2025-10-31. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Steve Barker
Analyst, Jefferies
Tony Rensan
Analyst, Macquarie
Norika Yamaji
Journalist, Nikkei Biotechnology & Business
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Daiichi Sankyo Company, Limited.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.076 Ladies and gentlemen, 00:00:05.042 -- 00:00:08.911 we would like to start FI 2025 Q2 00:00:08.911 -- 00:00:15.001 financial result presentation. My name is Asakura, in charge of corporate communication. 00:00:15.117 -- 00:00:19.324 In this presentation session, we are going to use both Japanese and English. 00:00:19.324 -- 00:00:25.353 We have simultaneous interpretation service available, so please make sure you click 00:00:25.353 -- 00:00:29.499 on the language button to choose the language of your preference. 00:00:29.499 -- 00:00:32.043 We have Japanese, English, and original audio. 00:00:32.043 -- 00:00:36.690 If you select an original audio, you should be able to hear original audio. 00:00:36.690 -- 00:00:42.159 And on the Zoom screen, we are going to present both Japanese and English presentation 00:00:42.159 -- 00:00:47.729 material. And for the live streaming, we are going to present the Japanese presentation 00:00:47.729 -- 00:00:51.235 material. Our corporate website, 00:00:51.235 -- 00:00:56.665 our library, earnings score related material page carries the presentation material 00:00:56.665 -- 00:01:01.714 both in Japanese and English. And let me introduce today's speakers. 00:01:01.714 -- 00:01:06.552 We have Representative representative director and CEO Okuzawa. 00:01:06.552 -- 00:01:09.640 We have the head of global R&D, Takeshita. 00:01:09.640 -- 00:01:13.791 We have Ken Keller, who is the director and oncology business head. 00:01:13.791 -- 00:01:19.277 We have CFO Ogawa. First, Okuzawa and Takeshita will offer you the explanation 00:01:19.277 -- 00:01:23.763 of the highlights of the second quarter result, and we are going to receive questions 00:01:23.763 -- 00:01:29.149 from investors and analysts by 5 p.m. Medi...